Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.

Latest Post

June 13, 2019

Key Takeaways from FDA Public Meeting on Outsourcing Facilities, cGMP and Office Stock

Members of the West Pharmaceutical Services, Inc. (West) Marketing Unit had the pleasure of attending the recent FDA Public Meeting on Tuesday, May 21, 2019 regarding 503B Compounding Pharmacies and the cGMP draft guidance, as well as office stock issues which had generated many comments.
West Pharma

Melanie Prudom

Director, Market Insights, Pharma


Search the Blog





  • Previous Posts
    Introducing Integrated Solutions

    May 02, 2019

    FDA Guidance Affecting cGMP Compounding Pharmacies (503Bs)

    Amy Kim

    Amy Kim

    Sr. Specialist, Scientific Communications, SA & TS

    SmartDose Injection Platform in Use

    October 16, 2018

    Medical Device User Fee Rates

    Ana Ladino

    Ana Ladino

    Director, Regulatory Affairs

    Blue West logo with Diamond

    April 16, 2014

    New FDA Guidance Issued for Annual Reportable Changes

    Steve LoCastro

    Steve LoCastro

    Director, Regulatory Affairs

    Load more